StreetInsider.com News Articles

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

Cipla Limited (BSE: 500087, NSE: CIPLA EQ) has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for a generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg.

Advair Diskus is a combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease. According to IQVIA, the U.S. market for fluticasone propionate and salmeterol inhalation powder is approximately $908 million.

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla wins FDA approval for generic Advair Diskus in all strengths

Tue, 28 Jul 2026 08:00:21 -0400

The approval is the first dry powder inhaler clearance from Cipla's U.S.-based manufacturing network, specifically its New York facility, according to the company's

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

MUMBAI, India and WARREN, N.J., July 28, 2026 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"), today announced that Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Tue, 28 Jul 2026 08:00:00 -0400

(Fluticasone Propionate and Salmeterol Inhalation Powder), across all three strengths